Introduction {#sec1-1}
============

Gastroesophageal reflux disease (GERD) is one of the common gastrointestinal problems around the world. The reported prevalence of GERD is approximately 10--20% in Western countries and less than 5% in Asia.\[[@ref1]\] Heartburn and regurgitation are its classic manifestations although extra-esophageal manifestations such as asthma, chronic laryngitis, and sinusitis are also frequently seen.\[[@ref2][@ref3][@ref4]\] Known risk factors of GERD include obesity, hiatal hernia, use of certain medications such as calcium channel blocker, anticholinergic, and tricyclic antidepressant.\[[@ref5][@ref6][@ref7]\] Untreated GERD can lead to several long-term complications including esophageal stricture, Barrett\'s esophagitis, and esophageal cancer.\[[@ref8][@ref9][@ref10]\]

Statins or hydroxymethylglutaryl-CoA reductase inhibitors are one of the most commonly used medications worldwide as a result of the global epidemic of metabolic syndrome and cardiovascular diseases.\[[@ref11]\] Previous studies suggested that the benefit of statins goes beyond the conventional cholesterol-lowering effect as they also have anti-inflammatory and immunomodulatory property.\[[@ref12][@ref13][@ref14]\] Interestingly, studies have suggested that use of statins is associated with a lower risk of Barrett\'s esophagus and esophageal cancer.\[[@ref15][@ref16][@ref17]\] Since GERD is one of the important risk factors for esophageal cancer, the observations raise an interesting question whether the reduced risk of esophageal cancer by statins run through the protective effect against GERD. In fact, the decreased risk of GERD among statin users is observed by some epidemiologic studies although the results were inconclusive.\[[@ref18][@ref19][@ref20]\] These systematic review and meta-analysis were conducted with the aim to summarize all available evidence to assess the risk of GERD among statin users versus nonusers.

Methods {#sec1-2}
=======

Search strategy {#sec2-1}
---------------

Two investigators (K. W. and P. U.) independently searched for published studies indexed in the MEDLINE and EMBASE database from inception to December 2017 using the search strategy that included the terms "gastroesophageal reflux disease," "reflux esophagitis," "Hydroxymethylglutaryl-CoA Reductase Inhibitors," and "Statins" as described in Online Supplementary Data 1. A manual search for additional studies using references of selected retrieved articles was also performed. No language limitation was applied in this study. This study was conducted in accordance to the PRISMA (Preferred reporting Items for Systematic Reviews and Meta-Analysis) statement which is provided as Online Supplementary Data 2. EndNote X7 (Clarivate Analytics, Pennsylvania, United States) was used for study retrieval.

Inclusion criteria {#sec2-2}
------------------

The inclusion criteria were as follows: (1) case-control, cross-sectional, or cohort studies that compared the risk of GERD among subjects who use statins compared with subjects who do not use statins, (2) odds ratios (ORs), relative risks (RR), hazard ratios (HR), or standardized incidence ratios (SIR) with 95% confidence intervals (CIs) or sufficient raw data to calculate these ratios were provided.

Study eligibility was independently determined by three investigators (K. W., P. P., and P. U.). Differences in the determination of study eligibility were resolved by mutual consensus. The quality of each study was also independently evaluated by each investigator using the validated Newcastle--Ottawa quality assessment scale.\[[@ref21]\] This scale evaluated each study in three domains including the selection of the participants, the comparability between the groups as well as the ascertainment of the exposure of interest for case-control study, and the outcome of interest for cohort study. The modified Newcastle--Ottawa scale as described by Herzog *et al*. was used for cross-sectional study.\[[@ref22]\] Kappa statistics were used for evaluation of inter-rater agreement on Newcastle--Ottawa scale.

Data extraction {#sec2-3}
---------------

A standardized data collection form was used to extract the following data from each study: title of the study, name of the first author, year(s) when the study was conducted, year when the study was published, country where the study was conducted, number of subjects, demographic data of subjects, methods used to diagnose GERD, methods used to verify statins use, adjusted effect estimates with 95% CIs, and covariates that were adjusted in the multivariate analysis.

To ensure the accuracy of data extraction, this process was independently conducted by three investigators (K. W., P. P., and P. U.). Case record forms were crosschecked and any data discrepancy was also resolved by referring back to the original articles.

Statistical analysis {#sec2-4}
--------------------

Data analysis was performed using Review Manager 5.3 software from the Cochrane Collaboration (London, United Kingdom). Adjusted point estimates from each study were combined using the generic inverse variance method of DerSimonian and Laird which assigned the weight of each study in reverse to its variance.\[[@ref23]\] As the outcome of interest was relatively uncommon, we used RR of cohort study as an estimate for OR to combine with OR from case-control study and cross-sectional study. In light of the possible high between-study variance due to different study designs and populations, we used a random-effect model rather than a fixed-effect model. Cochran\'s *Q* test and *I*^2^ statistic were used to determine the between-study heterogeneity. This *I*^2^ statistic quantifies the proportion of total variation across studies, that is, due to heterogeneity rather than chance. A value of *I*^2^ of 0--25% represents insignificant heterogeneity, greater than 25% but less than or equal to 50% represents low heterogeneity, greater than 50% but less than or equal to 75% represents moderate heterogeneity, and greater than 75% represents high heterogeneity.\[[@ref24]\] We plan to use funnel plot to assess for the presence of publication bias.

Results {#sec1-3}
=======

Our search strategy yielded 960 potentially relevant articles (367 articles from MEDLINE and 593 articles from EMBASE). After the exclusion of 364 duplicated articles, 596 of them underwent title and abstract review. Five hundred and eighty-six articles were excluded at this stage since they were case reports, letters to editor, review articles, basic science studies, animal studies, or interventional studies, leaving 10 articles for full-length article review. Five of them were excluded since they did not report the outcome of interest whereas 1 article\[[@ref25]\] was excluded because it was a conference abstract that duplicated an original study.\[[@ref20]\] Finally, 4 studies (2 cross-sectional studies,\[[@ref6][@ref19]\] 1 case-control study,\[[@ref18]\] and 1 cohort study\[[@ref20]\]) with 14,505 participants were included in the data analysis. The literature review and study selection process are demonstrated in [Figure 1](#F1){ref-type="fig"}. The clinical characteristics and the quality assessment of the included studies are described in [Table 1](#T1){ref-type="table"}. PRISMA is provided as Online Supplementary Data 2. It should be noted that the inter-rater agreement for the quality assessment using the Newcastle--Ottawa scale was high with the kappa statistics of 0.75.
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###### 

Main characteristics of the studies included in this meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 Fujii *et al*.\[[@ref18]\]                                                                                                                                                Nakaji *et al*.\[[@ref19]\]                                                                                          Asaoka *et al*.\[[@ref6]\]                                                                                                        Smith *et al*.\[[@ref20]\]
  ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Country                                        Japan                                                                                                                                                                     Japan                                                                                                                Japan                                                                                                                             USA

  Study design                                   Case-control study                                                                                                                                                        Cross-sectional study                                                                                                Cross-sectional study                                                                                                             Retrospective cohort study

  Year of publication                            2009                                                                                                                                                                      2011                                                                                                                 2016                                                                                                                              2017

  Number of subjects                             438 (146 cases with GERD and 292 controls without GERD)                                                                                                                   201 (17 patients with GERD and 184 patients without GERD)                                                            1182 (127 patients with GERD and 1055 patients without GERD)                                                                      12,684 (6342 statin-users and 6342 nonusers)

  Baseline characteristics of participants       Male: 58.2%\                                                                                                                                                              Male: 47%\                                                                                                           Male: 64.6%\                                                                                                                      Male: 53.9%\
                                                 Mean age: 66.7±12.3 years                                                                                                                                                 Mean age: 70.5±12.7 years                                                                                            Mena age: 58.9±13.3 years\                                                                                                        Mean age: 55.7±12.4 years\
                                                                                                                                                                                                                                                                                                                                                Mean BMI: 24.6±3.9 kg/m^2^                                                                                                        Overweight/Obesity: 15.1%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Smoking: 8.0%

  Comorbidity                                    N/A                                                                                                                                                                       Atrial fibrillation: 52.9%\                                                                                          Barrett's mucosa: 38.6%\                                                                                                          Coronary atherosclerosis: 5.0%\
                                                                                                                                                                                                                           Coronary artery disease: 29.4%\                                                                                      Hiatal hernia: 75.6%                                                                                                              Cerebrovascular disease: 2.0%\
                                                                                                                                                                                                                           Stroke: 11.8%\                                                                                                                                                                                                                                         Diabetes mellitus: 12.4%\
                                                                                                                                                                                                                           Diabetes mellitus and heart failure: 0.0%\                                                                                                                                                                                                             Diabetes mellitus with complications: 3.9%\
                                                                                                                                                                                                                           Hypertension: 29.4%                                                                                                                                                                                                                                    Acute myocardial infarction: 0.4%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Hypertension: 2.9%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Asthma: 5.8%

  Concurrent medication                          Antiplatelet agents: 26%\                                                                                                                                                 Warfarin: 64.7%\                                                                                                     PPI: 24.4%\                                                                                                                       NSAIDs: 58.4%\
                                                 Aspirin: 22.6%\                                                                                                                                                           Antiplatelet agents: 35.3%\                                                                                          H2RA: 10.2%\                                                                                                                      PPI: 32%\
                                                 Warfarin: 6.8%\                                                                                                                                                           ARB, ACEI: 35.3%\                                                                                                    CCB: 26.8%\                                                                                                                       Aspirin: 29.8%\
                                                 PPI: 11.0%                                                                                                                                                                CCB: 70.6%\                                                                                                          Bisphosphonates: 3.1%                                                                                                             Beta-blocker: 17.7%\
                                                                                                                                                                                                                           Antiarrhythmic drugs: 35.3%\                                                                                                                                                                                                                           SSRI: 16.8%\
                                                                                                                                                                                                                           Beta-blockers: 41.2%\                                                                                                                                                                                                                                  CCB: 15.8%\
                                                                                                                                                                                                                           Gastric medicine: 64.7%                                                                                                                                                                                                                                Nonstatin lipid-lowering drug: 6.2%

  Recruitment of subjects                        Cases: Cases were those who underwent upper endoscopy at Gunma Prefectural Cardiovascular Center (Japan) from December 2005 to October 2007 and was found to have GERD\   Subjects were recruited from cardiology outpatient clinics in Kyushu, Japan between January 2008 and February 2010   Subjects were those who underwent upper endoscopy at Jutendo University Hospital, Japan between February 2008 and November 2014   Cohorts of statin users and nonusers were identified from a regional Military Healthcare System database from October 1, 2003 to March 1, 2012
                                                 Controls: Controls were those who underwent upper endoscopy at the same medical center but were not found to have GERD                                                                                                                                                                                                                                                                                                           

  Definition of statin use                       Use of pravastatin, rosuvastatin, atorvastatin, simvastatin, or pitivastatin within 7 days prior to the endoscopy                                                         Current use of statins on the date of the survey                                                                     Use of statin for at least 6 months until the date of upper endoscopy                                                             Presence of prescription (s) for statins in medical records before the index date

  Diagnosis of GERD                              Presence of reflux esophagitis on upper endoscopy                                                                                                                         GERD was diagnosed using the Frequency Scale for Symptoms of GERD questionnaire (cutoff value of 8)                  Presence of reflux esophagitis on upper endoscopy                                                                                 Presence of diagnostic codes for GERD in the database

  Confounder adjusted in multivariate analysis   Use of aspirin, H2 blockers, proton pump inhibitors and hiatal hernia                                                                                                     None                                                                                                                 Sex, BMI, *H. pylori* infection, medications (CCB), and upper GI findings (Barrett's mucosa, hiatal hernia, EGA)                  Age, sex, and comorbidities

  Quality assessment (Newcastle-Ottawa scale)    Selection: 2                                                                                                                                                              Selection: 2                                                                                                         Selection: 3                                                                                                                      Selection: 3

  Comparability: 2                               Comparability: 2                                                                                                                                                          Comparability: 2                                                                                                     Comparability: 2                                                                                                                  

  Outcome: 3                                     Outcome: 2                                                                                                                                                                Outcome: 3                                                                                                           Outcome: 2                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GERD: Gastroesophageal reflux disease, GI: Gastrointestinal, BMI: Body mass index, *H. pylori*: *Helicobacter pylori*, EGA: Endoscopic gastric mucosal atrophy, PPI: Proton pump inhibitors, H2RA: Histamine-2-receptor antagonists, ACEI: Angiotensin converting enzyme inhibitors, ARB: Angiotensin II receptor blockers, NSAIDs: Nonsteroidal anti-inflammatory drugs, SSRI: Selective serotonin receptor inhibitor, N/A: Not available, CCB: Calcium channel blockers

In this meta-analysis, the risk of GERD among statin users was numerically lower than nonusers with the pooled OR of 0.89 but the result did not achieve statistical significance (95% CI, 0.60--1.33). The heterogeneity in this study was moderate (*I*^2^ = 54%). The forest plot of this study is shown in [Figure 2](#F2){ref-type="fig"}. Funnel plot was not used to assess for the presence of publication bias due to the small number of included studies.
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Discussion {#sec1-4}
==========

To date, there is no systematic review of the effects of statins on GERD available in the Cochrane database and the current study is the first systematic review and meta-analysis to assess the protective effect of statins against development of GERD. We found that the risk of GERD was numerically lower among statin users compared with nonusers although the pooled result did not reach statistical significance which could be due to the lack of power as a result of small number of included studies and participants.

There are few theoretical explanations as to why use of statins may decrease the risk of GERD. Nitric oxide plays an important role in the regulation of the lower esophageal sphincter tone.\[[@ref26][@ref27]\] Increased nitric oxide level induces relaxation of the lower esophageal sphincter which could predispose patients to GERD. A study in rat has demonstrated that statins can decrease nitric oxide production which may help increasing the lower esophageal sphincter tone.\[[@ref28]\] Oxidative stress and inflammatory cytokines are important players in the pathogenesis of GERD.\[[@ref29][@ref30][@ref31]\] Therefore, use of statins could possibly decrease the risk of GERD through their anti-oxidative and anti-inflammatory effect. However, epidemiologic studies on the association between use of statins and risk of GERD have yielded conflicting results, ranging from a significantly higher risk of GERD among statin users to a significantly higher risk of GERD among nonusers. The current study was conducted with the aim to take the advantage of systematic review and meta-analysis technique to summarize data from all studies. However, we still do not have enough power to demonstrate that the risk of GERD is significantly lower among statin users. In addition, the current study has some limitations that need to be acknowledged. First, all of the included studies were observational in nature and all but one study were either cross-sectional or case-control studies which were of less reliability compared with cohort studies to address the exposure-outcome dynamics. Second, adjustment for potential confounder in each study was not extensive (one study was unadjusted), and thus, influence of those factors on the outcome of interest could not be excluded. Moreover, the between-studies heterogeneity of this meta-analysis was not low. Therefore, the current systematic review and meta-analysis can only serve as preliminary data and further studies with a more vigorous study design are still needed to clarify this potential benefit of statins.

Conclusion {#sec1-5}
==========

In summary, no statistically significant impact of statins on GERD was observed in this systematic review and meta-analysis.
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